+

WO2007150075A3 - Compositions comprenant du meloxicam nanoparticulaire et de l'hydrocodone à libération contrôlée - Google Patents

Compositions comprenant du meloxicam nanoparticulaire et de l'hydrocodone à libération contrôlée Download PDF

Info

Publication number
WO2007150075A3
WO2007150075A3 PCT/US2007/072054 US2007072054W WO2007150075A3 WO 2007150075 A3 WO2007150075 A3 WO 2007150075A3 US 2007072054 W US2007072054 W US 2007072054W WO 2007150075 A3 WO2007150075 A3 WO 2007150075A3
Authority
WO
WIPO (PCT)
Prior art keywords
hydrocodone
compositions
composition
component
controlled release
Prior art date
Application number
PCT/US2007/072054
Other languages
English (en)
Other versions
WO2007150075A2 (fr
Inventor
Paul Stark
John Devane
Niall Fanning
Gary Liversidge
Scott Jenkins
Gurvinder Singh-Rekhi
Original Assignee
Elan Pharma Int Ltd
Paul Stark
John Devane
Niall Fanning
Gary Liversidge
Scott Jenkins
Gurvinder Singh-Rekhi
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharma Int Ltd, Paul Stark, John Devane, Niall Fanning, Gary Liversidge, Scott Jenkins, Gurvinder Singh-Rekhi filed Critical Elan Pharma Int Ltd
Priority to AU2007260822A priority Critical patent/AU2007260822B2/en
Priority to EP07784540A priority patent/EP2032139A4/fr
Priority to CA002660650A priority patent/CA2660650A1/fr
Priority to MX2008016115A priority patent/MX2008016115A/es
Priority to JP2009516757A priority patent/JP2009541360A/ja
Publication of WO2007150075A2 publication Critical patent/WO2007150075A2/fr
Publication of WO2007150075A3 publication Critical patent/WO2007150075A3/fr
Priority to IL196066A priority patent/IL196066A0/en
Priority to NO20090119A priority patent/NO20090119L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5138—Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5026—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Nanotechnology (AREA)
  • Rheumatology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Cette invention concerne des compositions comprenant une composition de meloxicam nanoparticulaire combinée à une composition d'hydrocodone multiparticulaire à libération modifiée qui, après administration à un patient, libère un hydrocodone sous une forme bimodale ou multimodale. La composition multiparticulaire à libération modifiée comprend un premier constituant et au moins un constituant subséquent. Le premier constituant comprend une première population de particules contenant de l'hydrocodone; et le ou les constituants subséquents comprennent une seconde population de particules contenant de l'hydrocodone. Ces constituants combinés présentent un profil de libération bimodale ou multimodale. L'invention concerne en outre une forme posologique orale solide comprenant cette composition combinée.
PCT/US2007/072054 2006-06-23 2007-06-25 Compositions comprenant du meloxicam nanoparticulaire et de l'hydrocodone à libération contrôlée WO2007150075A2 (fr)

Priority Applications (7)

Application Number Priority Date Filing Date Title
AU2007260822A AU2007260822B2 (en) 2006-06-23 2007-06-25 Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
EP07784540A EP2032139A4 (fr) 2006-06-23 2007-06-25 Compositions comprenant du meloxicam nanoparticulaire et de l'hydrocodone à libération contrôlée
CA002660650A CA2660650A1 (fr) 2006-06-23 2007-06-25 Compositions comprenant du meloxicam nanoparticulaire et de l'hydrocodone a liberation controlee
MX2008016115A MX2008016115A (es) 2006-06-23 2007-06-25 Composiciones que comprenden meloxicam nanoparticulado e hidrocodona de liberacion controlada.
JP2009516757A JP2009541360A (ja) 2006-06-23 2007-06-25 ナノ粒子状メロキシカムおよび制御放出ヒドロコドンを含む組成物
IL196066A IL196066A0 (en) 2006-06-23 2008-12-18 Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone
NO20090119A NO20090119L (no) 2006-06-23 2009-01-09 Sammensetning omfattende nanopartikulaert meloxicam og hydrokodon med kontrollert frigivelse

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US81588406P 2006-06-23 2006-06-23
US60/815,884 2006-06-23

Publications (2)

Publication Number Publication Date
WO2007150075A2 WO2007150075A2 (fr) 2007-12-27
WO2007150075A3 true WO2007150075A3 (fr) 2008-04-24

Family

ID=38834447

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/072054 WO2007150075A2 (fr) 2006-06-23 2007-06-25 Compositions comprenant du meloxicam nanoparticulaire et de l'hydrocodone à libération contrôlée

Country Status (11)

Country Link
EP (1) EP2032139A4 (fr)
JP (1) JP2009541360A (fr)
KR (1) KR20090023729A (fr)
CN (1) CN101484169A (fr)
AU (1) AU2007260822B2 (fr)
CA (1) CA2660650A1 (fr)
IL (1) IL196066A0 (fr)
MX (1) MX2008016115A (fr)
NO (1) NO20090119L (fr)
WO (1) WO2007150075A2 (fr)
ZA (1) ZA200810098B (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8808740B2 (en) 2010-12-22 2014-08-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9522135B2 (en) 2009-04-24 2016-12-20 Iceutica Pty Ltd. Formulation of indomethacin

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040253310A1 (en) 2001-09-21 2004-12-16 Gina Fischer Morphine polymer release system
EP2957281A1 (fr) 2001-09-21 2015-12-23 Egalet Ltd. Systeme de liberation a base de polymere
EP1610767B1 (fr) 2003-03-26 2011-01-19 Egalet A/S Systeme de liberation regulee de morphine
US8821928B2 (en) 2007-06-04 2014-09-02 Egalet Ltd. Controlled release pharmaceutical compositions for prolonged effect
US20090311335A1 (en) * 2008-06-12 2009-12-17 Scott Jenkins Combination of a triptan and an nsaid
CA2751667C (fr) 2009-02-06 2016-12-13 Egalet Ltd. Composition a liberation immediate resistant a une maltraitance par prise d'alcool
EP2435027B1 (fr) 2009-05-27 2016-10-05 Alkermes Pharma Ireland Limited Réduction des agrégats sous forme de paillettes dans des compositions nanoparticulaires de méloxicam
WO2010149169A2 (fr) 2009-06-24 2010-12-29 Egalet A/S Formulations à libération contrôlée
PH12013501345A1 (en) 2010-12-23 2022-10-24 Purdue Pharma Lp Tamper resistant solid oral dosage forms
EP2586429A1 (fr) * 2011-10-26 2013-05-01 Freund Pharmatec Ltd. Dispositif d'administration de médicaments à plusieurs unités pour libération pulsatile ou prolongée
CN103070906A (zh) * 2011-12-08 2013-05-01 赵联华 一种治疗骨科疾病的注射用组合物的质量控制方法
KR101785414B1 (ko) * 2011-12-29 2017-10-16 라보라토리오스 안드로마코 에스.에이. 여성에서 연속 사용 피임제로서 사용될 수 있는, 멜록시캄 및 유효 성분 방출 조절제를 포함하는 질 고리
JP2015521988A (ja) 2012-07-06 2015-08-03 イガレット・リミテッド 制御放出用乱用防止性医薬組成物
US10751287B2 (en) 2013-03-15 2020-08-25 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9526734B2 (en) 2014-06-09 2016-12-27 Iceutica Pty Ltd. Formulation of meloxicam
US9132096B1 (en) 2014-09-12 2015-09-15 Alkermes Pharma Ireland Limited Abuse resistant pharmaceutical compositions
WO2021257784A1 (fr) * 2020-06-18 2021-12-23 Verté Therapeutics, Llc Formulations de méloxicam injectables
CN113181249B (zh) * 2021-05-25 2022-06-14 重庆市畜牧科学院 一种抗仔猪腹泻的中药缓释颗粒的制备方法

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040176402A1 (en) * 2000-02-08 2004-09-09 Benjamin Oshlack Controlled-release compositions containing opioid agonist and antagonist
US20040229038A1 (en) * 2003-03-03 2004-11-18 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations
US20040266807A1 (en) * 1999-10-29 2004-12-30 Euro-Celtique, S.A. Controlled release hydrocodone formulations

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS49982B (sr) * 1997-09-17 2008-09-29 Euro-Celtique S.A., Sinergistička analgetička kombinacija analgetičkog opijata i inhibitora ciklooksigenaze-2
EP1126826B3 (fr) * 1998-11-02 2019-05-15 Alkermes Pharma Ireland Limited Composition de methylphenidate a liberation modifiee multiparticulaire
ATE371442T1 (de) * 2001-10-12 2007-09-15 Elan Pharma Int Ltd Zusammensetzungen mit einer kombination aus eigenschaften sofortiger freisetzung und kontrollierter freisetzung

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040266807A1 (en) * 1999-10-29 2004-12-30 Euro-Celtique, S.A. Controlled release hydrocodone formulations
US20040176402A1 (en) * 2000-02-08 2004-09-09 Benjamin Oshlack Controlled-release compositions containing opioid agonist and antagonist
US20040229038A1 (en) * 2003-03-03 2004-11-18 Elan Pharma International Ltd. Nanoparticulate meloxicam formulations

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9522135B2 (en) 2009-04-24 2016-12-20 Iceutica Pty Ltd. Formulation of indomethacin
US8808740B2 (en) 2010-12-22 2014-08-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9393206B2 (en) 2010-12-22 2016-07-19 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9572779B2 (en) 2010-12-22 2017-02-21 Purdue Pharma L.P. Encased tamper resistant controlled release dosage forms
US9149533B2 (en) 2013-02-05 2015-10-06 Purdue Pharma L.P. Tamper resistant pharmaceutical formulations
US9579389B2 (en) 2013-02-05 2017-02-28 Purdue Pharma L.P. Methods of preparing tamper resistant pharmaceutical formulations

Also Published As

Publication number Publication date
CA2660650A1 (fr) 2007-12-27
MX2008016115A (es) 2009-01-20
IL196066A0 (en) 2009-09-01
CN101484169A (zh) 2009-07-15
WO2007150075A2 (fr) 2007-12-27
JP2009541360A (ja) 2009-11-26
ZA200810098B (en) 2009-12-30
KR20090023729A (ko) 2009-03-05
EP2032139A2 (fr) 2009-03-11
AU2007260822B2 (en) 2012-07-05
AU2007260822A1 (en) 2007-12-27
EP2032139A4 (fr) 2012-08-22
NO20090119L (no) 2009-03-20

Similar Documents

Publication Publication Date Title
WO2007150075A3 (fr) Compositions comprenant du meloxicam nanoparticulaire et de l'hydrocodone à libération contrôlée
WO2007150074A3 (fr) Compositions comprenant du naproxène nanoparticulaire et de l'hydrocodone à libération contrôlée
WO2006102610A3 (fr) Composes bicycloheteroaryle utilises en tant que modulateurs de p2x7 et leurs utilisations
WO2007109192A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109172A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109160A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2007109154A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 modulators et leurs utilisations
WO2007109182A3 (fr) Composés de bicyclohétéroaryle en tant que modulateurs de p2x7 et leurs utilisations
WO2009087634A3 (fr) Méthodes et compositions pour l'administration orale d'insuline
WO2006002365A3 (fr) Microparticules fortement chargees en agent bioactif
WO2007042271A3 (fr) Nouvelle utilisation de compositions nutraceutiques
WO2009108720A3 (fr) Antagonistes des récepteurs d2 de la prostaglandine
WO2008033351A3 (fr) Formulations multimode de libération prolongée et résistantes à l'abus
WO2007109201A3 (fr) Composés de bicyclohétéroaryle en tant que modulateur de p2x7 et leurs utilisations
WO2006124047A3 (fr) Formulations pharmaceutiques contenant des microparticules ou des nanoparticules d'un agent d'administration
WO2010057118A3 (fr) Antagonistes hétérocycliques des récepteurs de la prostaglandine d2
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
WO2006099514A3 (fr) Composition d'administration de medicaments contenant un polymere et un agent modificateur
WO2010019239A3 (fr) Composition pharmaceutique et administrations de celle-ci
WO2011106416A3 (fr) Formulations à l'épreuve d'un usage abusif
WO2007092755A3 (fr) Traitement de l'insuffisance et de la deficience de vitamine d avec de la 25-hydroxyvitamine d2 et de la 25-hydroxyvitamine d3
IL196426A (en) Micro-particles based on amphiphilic copolymer, their preparation processes and their pharmaceutical preparations
MY144857A (en) Phamaceutical composition comprising amlodipine and losartan
WO2010066749A3 (fr) Comprimés d'ulipristal acétate
WO2009050136A3 (fr) Procédé de traitement du syndrome de cushing

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780023516.6

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07784540

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2007260822

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2660650

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2007784540

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: MX/A/2008/016115

Country of ref document: MX

WWE Wipo information: entry into national phase

Ref document number: 196066

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2009516757

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2007260822

Country of ref document: AU

Date of ref document: 20070625

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 1020097001440

Country of ref document: KR

NENP Non-entry into the national phase

Ref country code: RU

ENPW Started to enter national phase and was withdrawn or failed for other reasons

Ref document number: PI0713038

Country of ref document: BR

Free format text: RETIRADO O PEDIDO POR NAO CUMPRIMENTO DA EXIGENCIA DA RPI 2149 DE 13/03/2012.

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载